A Product and Pipeline Analysis of the Global Knee Cartilage Repair Market

A New Standard of Care May be on the Horizon

Regular Price: USD 5,000

Special Price USD 4,500

10% OFF

* Required Fields

Regular Price: USD 5,000

Special Price USD 4,500

PAY BY INVOICE

Be the first to review this product

The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product and pipeline assessment is provided for marketed and investigational autologous cell-based therapy, allogenic cell-based therapy, and non-cellular products in the global, US, and European markets. Product profiles are included for companies that are currently or imminently marketing cell-based regenerative therapies and conducting clinical trials in the United States and Europe.

Table of Contents

Executive SummaryKey FindingsKey Findings (continued)The Ideal Knee Chondral Defect Repair SolutionKey Companies to WatchOther Companies to WatchMarket OverviewMarket DefinitionsMarket OpportunityMarket OverviewMarket Overview (continued)Market Overview (continued)Market Overview (continued)Market Overview (continued)Market Overview (continued)Market Overview (continued)Market Overview (continued)Current Cartilage Treatment OptionsSignificant Unmet Need Continues to Exist for Patients with Grades 3 and 4 Knee Chondral DefectsTechnology Improvement Increases Product UtilityMarket Drivers and RestraintsRecent Market DevelopmentsRecent Market Developments (continued)Global Competitive LandscapeKnee Cartilage Repair Market—Competitive Landscape of Key Products Knee Cartilage Repair Market—Competitive Landscape of Key Products (continued) Differentiators for Key Marketed and Pipeline ProductsDifferentiators for Key Marketed and Pipeline Products (continued)Differentiators for Key Marketed and Pipeline Products (continued)Competitive Landscape—Pivotal Phase 3 Trials for Key ProductsCompetitive Landscape—Post-marketed Trials for Key ProductsGlobal Estimated Approval Timelines for Key ProductsRegulatory Pathway for Key ProductsUS Competitive LandscapeKnee Cartilage Repair Market—US Competitive Landscape of all Marketed and Pipeline ProductsMarketed Product Analysis of Key Products—USPipeline Analysis of Key Products—USUS Competitive Landscape—Pivotal Phase 3 TrialsUS Pivotal Phase 3 Trial DetailsUS Competitive Landscape—Post-marketed TrialsEurope Competitive LandscapeKnee Cartilage Repair Market—Europe Competitive Landscape of all Marketed ProductsKnee Cartilage Repair Market—Europe Competitive Landscape of all Pipeline ProductsKey Marketed Product Analysis—EuropeKey Marketed Product Analysis—Europe (continued)Key Product Pipeline Analysis—EuropeEurope Competitive Landscape—Pivotal Phase 3 TrialsEurope Pivotal Phase 3 TrialsEurope Pivotal Phase 3 Trials (continued)Europe Estimated Approval TimelinesDeep Dive Assessment of Key ParticipantsNeoCart—Timelines for Focal Cartilage DefectsNeoCart—Clinical Trial Design Approach and Key Published DataProduct Dashboard—NeoCartNovoCart 3D—US Timelines for Focal Cartilage DefectsNovoCart 3D—Europe Timelines for Focal Cartilage DefectsNovoCart 3D—Clinical Trial Design Approach and Key Published DataNovoCart 3D—Clinical Trial Design Approach and Key Published Data (continued)Product Dashboard—NovoCart 3DRevaFlex—Timelines for Focal Cartilage DefectsRevaFlex—Clinical Trial Design Approach and Key Published DataProduct Dashboard—RevaFlexCarticel—Clinical Trial Design Approach and Key Published DataCarticel—Clinical Trial Design Approach and Key Published Data (continued)Product Dashboard—CarticelMACI—Clinical Trial Design Approach and Key Published DataMACI—Clinical Trial Design Approach and Key Published Data (continued)Product Dashboard—MACIChondroCelect—Clinical Trial Design Approach and Key Published Data ChondroCelect—Clinical Trial Design Approach and Key Published Data (continued)Product Dashboard—ChondroCelectDeNovo NT—Clinical Trial Design Approach and Key Published DataDeNovo NT—Clinical Trial Design Approach and Key Published Data (continued)DeNovo NT—Clinical Trial Design Approach and Key Published Data (continued)Product Dashboard—DeNovo NTProduct Dashboard—CartiformProduct Dashboard—BioCartilageProduct Dashboard—CartistemKOL InsightsKey Opinion Leader (KOL) InsightsKey Opinion Leader (KOL) Insights (continued)ConclusionsConclusionsLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 20-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.